189560-87-0

Upstream product

• 6646-70-4 (1-benzyl-1H-benzo[d]imidazol-2-yl)methanol 
• 7755-92-2 piperazine-1-carbaldehyde 
• 7192-00-9 1-benzyl-2-(chloromethyl)-1H-benzo[d]imidazole 

Downstream Products

• 189560-86-9 1-benzyl-2-(piperazin-1-ylmethyl)-1H-benzo[d]imidazole 
• 1172074-20-2 1-benzyl-2-((4-(phenylsulfonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazole 
• 1172525-83-5 (4-((1-benzyl-1H-benzo[d]imidazol-2-yl)methyl)piperazin-1-yl)(phenyl)methanone 
• 1211330-70-9 4-((1-benzyl-1H-benzo[d]imidazol-2-yl)methyl)-N-phenylpiperazine-1-carboxamide 
• 1568975-31-4 benzyl 4-((1-benzyl-1H-benzo[d]imidazol-2-yl)methyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

BENZIMIDAZOLES FOR THE TREATMENT OF CANCER

The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.